268 related articles for article (PubMed ID: 24315712)
1. Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities.
Savasi I; Jayasinghe K; Moore P; Jayasinghe Y; Grover SR
J Pediatr Adolesc Gynecol; 2014 Feb; 27(1):25-8. PubMed ID: 24315712
[TBL] [Abstract][Full Text] [Related]
2. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
3. Uterine Length in Adolescents with Developmental Disability: Are Ultrasound Examinations Necessary before Insertion of the Levonorgestrel Intrauterine System?
Whyte H; Pecchioli Y; Oyewumi L; Kives S; Allen LM; Kirkham YA
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):648-652. PubMed ID: 27321898
[TBL] [Abstract][Full Text] [Related]
4. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
[TBL] [Abstract][Full Text] [Related]
5. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
[TBL] [Abstract][Full Text] [Related]
6. Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.
Kaislasuo J; Suhonen S; Gissler M; Lähteenmäki P; Heikinheimo O
Hum Reprod; 2012 Sep; 27(9):2658-63. PubMed ID: 22763376
[TBL] [Abstract][Full Text] [Related]
7. Pain and bleeding pattern related to levonorgestrel intrauterine system (LNG-IUS) insertion.
Van Schoubroeck D; Van den Bosch T; Ameye L; Veldman J; Hindryckx A; Werbrouck E; Timmerman D
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):154-6. PubMed ID: 24029596
[TBL] [Abstract][Full Text] [Related]
8. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
Barnett C; Moehner S; Do Minh T; Heinemann K
Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
[TBL] [Abstract][Full Text] [Related]
10. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
11. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding.
Wildemeersch D; Andrade A
Gynecol Endocrinol; 2010 May; 26(5):383-9. PubMed ID: 20192899
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal levonorgestrel-releasing intrauterine device following uterine perforation: the role of progestins in adhesion formation.
Haimov-Kochman R; Doviner V; Amsalem H; Prus D; Adoni A; Lavy Y
Hum Reprod; 2003 May; 18(5):990-3. PubMed ID: 12721174
[TBL] [Abstract][Full Text] [Related]
13. Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?
Patseadou M; Michala L
Arch Gynecol Obstet; 2017 Mar; 295(3):529-541. PubMed ID: 27928678
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system.
Youm J; Lee HJ; Kim SK; Kim H; Jee BC
Int J Gynaecol Obstet; 2014 Aug; 126(2):165-9. PubMed ID: 24825498
[TBL] [Abstract][Full Text] [Related]
15. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
Gardyszewska A; Czajkowski K
Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
[TBL] [Abstract][Full Text] [Related]
16. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
[TBL] [Abstract][Full Text] [Related]
17. Length of the endometrial cavity and intrauterine contraceptive device expulsion.
Bahamondes MV; Monteiro I; Canteiro R; Fernandes Ados S; Bahamondes L
Int J Gynaecol Obstet; 2011 Apr; 113(1):50-3. PubMed ID: 21272883
[TBL] [Abstract][Full Text] [Related]
18. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
Wildemeersch D; Goldstuck ND; Jackers G
Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
[TBL] [Abstract][Full Text] [Related]
19. Expulsions and adverse events following immediate and later insertion of a levonorgestrel-releasing intrauterine system after medical termination of late first- and second-trimester pregnancy: a randomised controlled trial.
Korjamo R; Mentula M; Heikinheimo O
BJOG; 2017 Dec; 124(13):1965-1972. PubMed ID: 28692170
[TBL] [Abstract][Full Text] [Related]
20. Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: case report.
Haimov-Kochman R; Amsalem H; Adoni A; Lavy Y; Spitz IM
Hum Reprod; 2003 Jun; 18(6):1231-3. PubMed ID: 12773451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
